CLERAD

What CLERAD does

CLERAD is a privately-held French medical device company founded in 2000 by physicist Philippe Brette and headquartered in Clermont-Ferrand, France, where it designs, develops, and manufactures its products in-house. The company specializes in ionizing radiation detection and surgical-guidance technologies, with a core portfolio of Class IIa/IIb devices including the GAMMA-SUP II isotopic detection probe, the GAMMA-NODE compact intraoperative gamma camera, the GAMMA-AM monitoring probe for isolated limb perfusion, the Iodine-125 radioactive seed for breast lesion localization, and (since the April 2026 acquisition of UK-based Ariane Medical Systems) the Papillon+ 50kV contact X-ray brachytherapy system for breast, skin, and rectal cancer. These devices support radioguided surgery workflows such as sentinel lymph node biopsy, FDG detection, and preoperative lesion localization in nuclear medicine, radiotherapy, surgery/oncology, radiology, and pathology departments.

The business model combines proprietary capital-equipment sales and recurring after-sales service/maintenance (with guaranteed 48-hour intervention from headquarters) with the distribution of complementary third-party products from manufacturers including Kubtec (specimen radiography), Scintron-MiE (gamma cameras), Mirion/Capintec (nuclear medicine equipment), and Reger (nebulizers). Pricing is quote-based under multi-year contracts, reflecting the consultative, B2B sale into hospitals and academic cancer centers. Commercial reach is delivered through specialized distribution partners selected for patient-safety standards across Europe, the Americas, Asia, and Africa — four continents in total — with regulatory access supported by ISO 13485 certification, CE marking under EU Regulation 2017/745, and FDA registration. Marketing is clinically oriented, anchored on peer-reviewed evidence (notably the OPERA trial), webinars, and participation in surgical-oncology symposia rather than direct-to-consumer channels. CLERAD's differentiation rests on its 25-year physics-engineering heritage, vertically integrated French manufacturing, and clinical validation of therapeutic de-escalation outcomes — for example, the OPERA trial's reported 81% rectal preservation rate at 3 years for contact X-ray brachytherapy versus 59% with external beam radiotherapy.

Name

CLERAD

Legal name

CLERAD

Website

https://clerad.fr

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Short description

CLERAD is a French privately-held medical device manufacturer founded in 2000, designing and producing ionizing radiation detection and surgical-guidance devices — including gamma probes, compact intraoperative gamma cameras, radioactive seed localization, and contact X-ray brachytherapy systems — for hospitals and oncology centers across four continents.

Ownership category

akta.pro rank

Product category

Radiation Detection and Radiotherapy Medical Devices

NAICS

Irradiation Apparatus Manufacturing (334517), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844)

akta.pro primary industry

Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology) (EUAKAIAD)

akta.pro secondary industries

Sealed Source Manufacturing, Encapsulation & Recycling/Take-Back (Source lifecycle management) (EUAKAIAI), Radiation Oncology (HLAKAFAC), Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI)

Keywords

• Radioguided surgery systems
• Contact X-ray brachytherapy
• Gamma detection probes
• Medical device manufacturing
• Nuclear medicine devices

Headquarters

HQ city

Clermont-ferrand

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Medical Device Sales: Sale of proprietary medical devices including gamma probes, gamma cameras, and contact radiotherapy systems. Products include GAMMA-SUP II, GAMMA-NODE, GAMMA-AM, Papillon+, and Iodine-125 seeds classified as Class IIa and IIb medical devices.
2. Distributed Products Sales: Distribution of third-party medical devices including Kubtec radiography systems (XPERT, MOZART, PICASSO), Mirion/Capintec equipment, and Reger nebulizers.
3. After-Sales Service and Maintenance: Maintenance and aftersales service provided directly from headquarters including guaranteed intervention within 48 hours. Technical support hotline for biomedical and clinical teams.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

CLERAD designs, develops, and manufactures proprietary Class IIa and IIb medical devices for ionizing radiation detection, specializing in radioguided surgery (gamma probes, gamma cameras, radioactive seeds) and contact X-ray brachytherapy (Papillon+ system). The portfolio is complemented by distributed third-party products from partners such as Kubtec, Scintron-MiE, Mirion/Capintec, and Reger. After-sales service and maintenance are provided directly from the Clermont-Ferrand headquarters.

Product overview

CLERAD is a French medical device company developing and manufacturing ionizing radiation detection and surgical guidance technologies. The product portfolio includes proprietary core products (GAMMA-SUP II probe, GAMMA-NODE compact gamma camera, GAMAM-AM monitoring probe, Papillon+ contact X-ray brachytherapy system, and Grain d'Iode-125 radioactive seed) alongside distributed products from partners including Scintron-MiE gamma cameras (PICOLA, SYNGULA, ECAM), Kubtec radiography systems (XPERT 20/40/80L, MOZART, PICASSO Plus), CAPINTEC/Mirion nuclear medicine equipment, SMARTVENT pulmonary ventilation, and Reger nebulizer. These devices support radioguided surgery techniques including sentinel lymph node biopsy (SLNB), SEED localization, and FDG detection across nuclear medicine, radiology, surgery, radiotherapy, and chemotherapy applications.

Differentiator

Problem solved

Functional benefit

Brands

• Papillon+: Contact XRAY Brachytherapy system for treatment of small accessible tumors of skin, breast, and rectum. Developed by acquired entity Ariane Medical Systems Ltd. (founded 2004).

Products and services

• GAMMA-SUP II Isotopic detection probe for radioguided surgery, designed for efficient detection of lymph nodes including deep or weakly radiolabelled nodes. Used in nuclear medicine for preoperative localization and in operating rooms for sentinel lymph node detection and extraction.
• GAMMA-NODE Compact gamma camera optimized for intraoperative identification assistance during surgical procedures.
• GAMMA-AM High sensitivity monitoring probe dedicated to isolated limb perfusion procedures.
• Papillon+ 50 kV contact X-ray brachytherapy system delivering optimal radiation dose to cancerous or suspected-cancerous tissues while preserving healthy tissues. Multimodality system adaptable to breast, skin, and rectal cancer applications with precise beam collimation and controlled depth penetration, treatment delivery in under 5 minutes and dose rate up to 25 Gy/min.
• Grain d'Iode-125 (Iodine-125 Seed) Sealed radioactive titanium seed emitting low-energy gamma radiation for preoperative localization of non-palpable breast lesions, enabling precise intraoperative lesion localization using a gamma probe.
• PICOLA Scintron - MiE Planar digital gamma camera system for thyroid imaging, described as versatile and effective. Distributed product from partner Scintron-MiE.
• SYNGULA Scintron - MiE Digital, versatile and efficient gamma camera system for clinical imaging applications. Distributed product from partner Scintron-MiE.
• ECAM Scintron - MiE Double-head NOVA SPECT system for nuclear medicine imaging. Distributed product from partner Scintron-MiE.
• CAPINTEC - Mirion Nuclear medicine equipment for improving diagnosis and treatment across the care pathway. Distributed product from partner Mirion/Capintec.
• XPERT 20 - Kubtec Radiography system designed for biopsy procedures, enabling sample imaging analysis. Distributed product from partner Kubtec.
• XPERT 40 - Kubtec Radiography system for specimen imaging in anatomical pathology. Distributed product from partner Kubtec.
• XPERT 80L - Kubtec Large sample radiography system for anatomical pathology services. Distributed product from partner Kubtec.
• MOZART - Kubtec Mobile enclosure for 3D radiography of surgical specimens, enabling intraoperative imaging of operative pieces. Distributed product from partner Kubtec.
• PICASSO Plus - Kubtec Sample radiography system for anatomical pathology departments. Distributed product from partner Kubtec.
• SMARTVENT Pulmonary ventilation system for respiratory support applications. Distributed product.
• Nebulizer - Reger Nebulization technology featuring four-nozzle power for aerosol drug delivery. Distributed product from partner Reger.

Quantifiable outcome

• 81% rectal preservation rate at 3 years with contact X-ray brachytherapy vs 59% with external beam radiotherapy (OPERA trial)
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Ariane Medical Systems Ltd.coreStrategic or Co-development Partner · 2 April 2026UK-based company specializing in development and commercialization of contact X-ray brachytherapy solutions (Papillon+). CLERAD acquired Ariane Medical Systems in April 2026, combining commercial and technical strengths across continents to ensure optimal field presence and support clients in using the Papillon+ system for contact therapy. Founded in 2004, AMS developed the Papillon+ technology for treatment of small, accessible tumors of skin, breast, and rectum.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Accuray: US-listed developer of CyberKnife and TomoTherapy radiation therapy systems used in radiation oncology departments. Broad incumbent competing for hospital radiotherapy budgets alongside CLERAD's Papillon+.
• Elekta: Swedish radiation therapy and radiosurgery giant offering brachytherapy afterloaders (Flexitron), linear accelerators, and neurosurgery solutions. Overlaps with CLERAD in radiation oncology and brachytherapy but operates at much broader scale.
• Carl Zeiss Meditec: Medical technology group offering surgical microscopy, intraoperative visualization, and ophthalmology/radiotherapy systems. Overlaps with CLERAD in surgical/radioguided procedures via complementary visualization technology.
• Varian Medical Systems (Siemens Healthineers): Global leader in radiation oncology with linear accelerators, treatment planning software, and brachytherapy solutions (e.g., Bravos afterloader). Competes broadly in radiation therapy departments where Papillon+ is sold.

Direct peers

• Hologic: Women's health leader whose breast surgery portfolio includes radioactive seed localization (RSL) and brachytherapy solutions such as SAVI. Directly competes with CLERAD's Iodine-125 seed and radioguided surgery products in breast cancer workflows.
• Theragenics: US manufacturer of brachytherapy seeds (I-125, Pd-103) and prostate treatment solutions. Direct peer in sealed brachytherapy source manufacturing alongside CLERAD's Iodine-125 product.
• IntraOp Medical: US-based developer of the Mobetron, a mobile electron beam intraoperative radiation therapy (IORT) system for cancer treatment. Directly competes with CLERAD's Papillon+ in the contact/superficial and intraoperative radiation therapy niche.
• IsoAid: Specialist manufacturer of Iodine-125 and Palladium-103 brachytherapy seeds used for prostate and other cancers. Closely comparable to CLERAD in the sealed source / seed manufacturing category.
• Eckert & Ziegler: German-headquartered manufacturer of radioactive sealed sources including Iodine-125 and Palladium-103 brachytherapy seeds. Direct competitor to CLERAD's Grain d'Iode-125 in the radioactive seed localization (RSL) market.

Emerging players

• iCAD: Specialist in AI-based cancer detection and radiation therapy solutions, including brachytherapy workflow software. Competes with CLERAD in selected radiation oncology workflow applications, primarily on the software/digital side.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/clerad

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CLERAD